Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients

British Journal of Cancer

Volumn 105, Issue 11, 2011, Pages 1663-1668

  Romano, S ^a   Fratini, S ^a   Ricevuto, E ^a   Procaccini, V ^a   Stifano, G ^a   Mancini, M ^a   Di Mauro, M ^a   Ficorella, C ^a   Penco, M ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

anthracyclines; brain natriuretic peptide; cardiac biomarkers; cardiotoxicity; N terminal pro brain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; TROPONIN I;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PRIORITY JOURNAL;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CYCLOPHOSPHAMIDE; DOXORUBICIN; ECHOCARDIOGRAPHY; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; TAXOIDS; TROPONIN I; TUMOR MARKERS, BIOLOGICAL; VENTRICULAR FUNCTION, LEFT;

EID: 81955164091     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.439     Document Type: Article

References (37)

1. Adamcova M, Sterba M, Simunek T, Potacova A, Popelova O, Mazurova Y, Gersl V (2005) Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 4: 457-472 (Pubitemid 40723720)
2. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H (2003) Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82: 218-222 (Pubitemid 36701012)
3. Bauch M, Ester A, Kimura B, Victorica BE, Kedar A, Phillips MI (1992) Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 69: 1492-1497
4. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM (2010) Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55: 213-220
5. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109: 2749-2754 (Pubitemid 38737923)
6. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36: 517-522
7. Dodos F, Halbsguth T, Erdmann E, Hoppe UC (2008) Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 97: 318-326 (Pubitemid 351725058)
8. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, Albrile F, Bobbio M, Merlano M (2011) Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 148: 194-198
9. Germanakis I, Kalmanti M, Parthenakis F, Nikitovic D, Stiakaki E, Vardas PE (2006) Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 108: 212-215 (Pubitemid 43330616)
10. Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4: 235-242 (Pubitemid 35190345)
11. Helmes M, Lim CC, Liao R, Bharti A, Cui L, Sawyer DB (2003) Titin determines the Frank-Starling relation in early diastole. J Gen Physiol 121: 97-110 (Pubitemid 36255340)
12. Helmes M, Trombitas K, Granzier H (1996) Titin develops restoring force in rat cardiac myocytes. Circ Res 79: 619-626 (Pubitemid 26276922)
13. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F, Coiffier B (2004) Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22: 1864-1871 (Pubitemid 41095177)
14. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, Celik I, Kes S, Tekuzman G (2005) cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 16: 798-804 (Pubitemid 40767103)
15. Kouloubinis A, Kaklamanis L, Ziras N, Sofroniadou S, Makaritsis K, Adamopoulos S, Revela I, Athanasiou A, Mavroudis D, Georgoulias V (2007) ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. Int J Cardiol 122: 195-201 (Pubitemid 47615179)
16. Latour-Pérez J, Coves-Orts FJ, Abad-Terrado C, Abraira V, Zamor J (2006) Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur J Heart Fail 8: 390-399 (Pubitemid 43842121)
17. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332: 1738-1743
18. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE (2004) The effects of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351: 145-153 (Pubitemid 38886649)
19. Mackay B, Ewer MS, Carrasco CH, Benjamin RS (1994) Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 18: 203-211 (Pubitemid 24131629)
20. Meinardi MT, Van Der Graaf WT, Gietema JA, Van Den Berg MP, Sleijfer DT, De Vries EG, Haaksma J, Boomsma F, Van Veldhuisen DJ (2002) Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques. Heart 88: 81-82 (Pubitemid 34665011)
21. Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, Volkers C, Haaksma J, de Vries EG, Sleijfer DT, van der Graaf WT (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19: 2746-2753 (Pubitemid 32441381)
22. Mele D, Pasanisi G, Capasso F, De Simone A, Morales MA, Poggio D, Capucci A, Tabacchi G, Sallusti L, Ferrari R (2006) Left intraventricular myocardial deformation dyssynchrony identifies responders to cardiac resynchronization therapy in patients with heart failure. Eur Heart J 27: 1070-1078
23. Mortensen SA, Olsen HS, Baandrup U (1986) Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 55: 274-282 (Pubitemid 16137871)
24. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22: 263-302 (Pubitemid 30213944)
25. Pichon MF, Cvitkovic F, Hacene K, Delaunay J, Lokiec F, Collignon MA, Pecking AP (2005) Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 19: 567-576 (Pubitemid 40568136)
26. Romano S, Necozione S, Guarracini L, Fratini S, Cisternino P, di Orio F, Penco M (2009) Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients. J Cardiovasc Med 10: 238-244
27. Rowan RA, Masek MA, Billingham ME (1988) Ultrastructural morphometric analysis of endomyocardial biopsies. Idiopathic dilated cardiomyopathy, anthracycline cardiotoxicity, and normal myocardium. Am J Cardiovasc Pathol 2: 137-144
28. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM (2005) N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 51: 1405-1410 (Pubitemid 41060872)
29. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2011) Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107: 1375-1380
30. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 53: 105-113
31. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R (2003) Health profiles in 5836 long-term cancer survivors. Int J Cancer 104: 488-495 (Pubitemid 36323921)
32. Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47-58
33. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905 (Pubitemid 28446849)
34. Sparano JA, Brown DL, Wolff AC (2002) Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2: 301-311 (Pubitemid 34634269)
35. Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, Kurabayashi M, Yamaoki K, Mitani K, Hirai H, Nagai R, Yazaki Y (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136: 362-363 (Pubitemid 28368863)
36. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53: 2231-2247
37. Wang SM, Greaser ML, Schultz E, Bulinski JC, Lin JJ, Lessard JL (1988) Studies on cardiac myofibrillogenesis with antibodies to titin, actin, tropomyosin, and myosin. J Cell Biol 107: 1075-1083